Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Leading Chinese Vaccine Developer Sinovac Conducts Technical Exchanges With Gates Foundation On Rotavirus Vaccine

This article was originally published in PharmAsia News

Executive Summary

BEIJING - China's leading vaccine developer, Sinovac Biotech, is applying for Chinese regulatory approval to launch clinical trials for two new pneumococcal polysaccharides vaccines

You may also be interested in...



Asia Innovators: Singapore's Inviragen In Race With Sinovac For HFMD Vaccine

SINGAPORE - Inviragen (Singapore) Pte Ltd is recruiting patients for its Phase I clinical trial in Singapore for its hand, foot and mouth disease vaccine INV21

Asia Innovators: Singapore's Inviragen In Race With Sinovac For HFMD Vaccine

SINGAPORE - Inviragen (Singapore) Pte Ltd is recruiting patients for its Phase I clinical trial in Singapore for its hand, foot and mouth disease vaccine INV21

China's State FDA Gets WHO Nod For Vaccine Regulatory System; Opens Global Market For Chinese Vaccine Makers

SHANGHAI - China's State FDA now complies with international standards for vaccine regulation and Chinese vaccine makers are eligible to apply for World Health Organization prequalification of vaccine products, WHO announced March 1, the same day that China implemented its newly revised good manufacturing practices (GMP) guidelines

Related Content

UsernamePublicRestriction

Register

SC077167

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel